Share Name Share Symbol Market Type Share ISIN Share Description
Synairgen Plc LSE:SNG London Ordinary Share GB00B0381Z20 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +1.00p +6.90% 15.50p 15.00p 16.00p 15.50p 14.50p 14.50p 101,676.00 12:28:22
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -2.6 -2.5 - 14.16

Synairgen Share Discussion Threads

Showing 476 to 500 of 500 messages
Chat Pages: 20  19  18  17  16  15  14  13  12  11  10  9  Older
DateSubjectAuthorDiscuss
27/10/2016
08:44
I did too, yesterday, they don't seem to like pi's buying
alphapig
27/10/2016
07:55
Dipped my toe in here today.
auphilman
21/10/2016
08:01
How low are the MMs gonna force this? it is already undervalued....
nakedsteve
14/10/2016
10:55
Nobby, yes I bought a few more on Wednesday.
timbo003
14/10/2016
09:34
I added a few more at 22p. I'm still well up on SNG from the time I first started buying between 18p and 25p in 2011(I sold a lot at 54p anf bought back lower). I've just been looking back at my old posts from then - happy times indeed. I was encouraged to see Griffiths buying As the FT commented last year. https://www.ft.com/content/f03a37f6-e4ea-11e4-8b61-00144feab7de And as one market sage observes: “You wouldn’t want to be a buyer if Woodford or Griffiths were sellers.”
ohisay
14/10/2016
09:22
>> Timbo As well as being at the Proactive presentations on Thursday last week, I was also at the Biotech conference on Tuesday. I saw Richard Marsden present and was quite impressed. Luckily I did nothing in the short term but I have to say the fall looks overdone as all is most definitely not lost for the product. Are you looking to buy at this level? TIA Nobby
nobbygnome
13/10/2016
19:58
Just watched the proactive video (post #420) which was shot immediately following the news that AZ will be terminated their study early. Richard Marsden sounds remarkably bullish and points out that there are potential upsides with respect to timings and data analysis. A bit of director buying now would help settle the nerves (I assume they are not currently in a closed period).
timbo003
13/10/2016
17:44
http://www.biopharmadive.com/news/next-stop-in-astrazeneca-fire-sale-china/428240/ AstraZeneca keeps hanging out the “for sale” sign. While diabetes care is an expanding market in many emerging markets like China, this latest deal reflects the British pharma’s strategy of shifting toward core therapeutic areas, such as oncology and respiratory, and selling off non-core assets.
ohisay
13/10/2016
10:17
http://www.synairgen.com/investors/major-shareholders/ Griffiths just added another 330k.
ohisay
12/10/2016
15:33
http://www.proactiveinvestors.co.uk/columns/broker-spotlight/26255/brokers-synairgen-still-a-buy-after-astra-decision-finncap-says-26255.html
ohisay
12/10/2016
15:28
http://www.proactiveinvestors.co.uk/companies/stocktube/6170/not-the-end-of-the-road-for-synairgens-asthma-treatment-6170.html
ohisay
12/10/2016
11:40
I think if you went for ER patients, you would still only enrol them onto the trial if the assignable cause for the exacerbation was a respiratory tract infection (I believe RT infections are the main cause for exacerbations in asthma and COPD so most of the asthma patients admitted to ER should meet with that required criteria). There is one potential problem with this approach (which Verona will have in their trial too), there are a lot of fatalities in ER rooms for respiratory patients, but perhaps mortality could become one of the secondary end points.
timbo003
12/10/2016
11:23
Maybe youre right about going for a possible "non flu" route. I was interested you said earlier they may have picked a low bar for entry because it didn't seem that way to me reading the trial req for volunteers. To have had at least two documented severe asthma exacerbations within the last 24 months that were suspected by the patient to have been caused by a common cold or flu and To have had at least one documented severe asthma exacerbation within the last 12 months that was suspected by the patient to have been caused by a common cold or flu I think they just got unlucky with the mildness of the flu symptoms this past year.I know I'm northern hemisphere but I can't recall having a bad case of flu for at least 2 years. For something that is so well tolerated and kills Swine flu/Bird flu 95% stone dead in the lab it seems a very unfortunate result. (PS I see Finncap havent changed their 137p target today)
ohisay
12/10/2016
10:32
Indeed, EV value must be less than total amount invested so far, so on that basis alone they must look cheap to someone like AZ. I've just been thinking about how they could have designed the study to give a better chance of a successful outcome. Perhaps it would have been better to go for an emergency room setting where all admitted asthma patients would have a severe exacerbation (otherwise they would not be there). Verona Pharma have opted for that sort of route for their late phase II /phase III clinicals on RPL554 for COPD.
timbo003
12/10/2016
09:38
EV now just 15m$ which is far too low for what they've already achieved. If AZN is really interested in progressing its respiratory business SNG would seem like an ideal add on . For example AZN's treatment for IPF (tralokinumab) has been dropped (though it may be OK for asthma) so a collaboration with SNG /PXS on its loxl research would make much sense.
ohisay
12/10/2016
08:39
>>>>Wookie, they are all listed in the link above
timbo003
12/10/2016
08:31
what are the secondary outcomes?
wookie77
12/10/2016
07:30
It sounds as if the number of infections is not the problem, it's the lack of severity in the symptoms. This is presumably a function of setting the bar too low for entry on to the trial and a mild cold and flu season. What is really required is a really nasty strain to come along (Swine flu or Bird flu?) which effects the lower RT rather than the upper RT, (i.e. more cough than cold). It's worth just revisiting the outline protocol https://clinicaltrials.gov/ct2/show/study/NCT02491684?term=asthma+interferon&;rank=1&show_locs=Y#locn AZ certainly commissioned enough centres in enough countries. On the positive side, they have a very large number of secondary outcomes to look at and with which to conduct the revised analysis.
timbo003
12/10/2016
07:24
Its always been a stock which moves on very little volume . Works both ways of course.!
ohisay
12/10/2016
07:13
Wow 30% drop on only 150,000 sales lol
wookie77
12/10/2016
06:56
Was always a risk they wouldnt get enough patients to have a statistically significant result at the end of thr trial. It seems the flu season over the past year has been quite benign worldwide and I'm sure thats had some effect on the level of "bad exacerbations". I'd doubt very much if AZN would drop the product at this stage.
ohisay
12/10/2016
06:32
Today's news is good for patients on the trial (less exacerbations than expected for all participants on the trial) but frustrating for Synairgen and Astra Zeneca. http://www.investegate.co.uk/synairgen-plc--sng-/rns/azd9412-clinical-trial-update/201610120700162831M/ I suspect the market reaction will be a substantial mark down at the open as this must add to the uncertainty regarding Astra Zeneca's ultimate decision whether or not to go ahead, but at least we know now that the decision will be taken before end of Q1/17. Although not stated in the RNS it wouldn't surprise me if we hear about their decision in the current quarter.
timbo003
12/10/2016
06:24
ok so nothing wrong with the product just not enough patients got colds! Is that how everyone else reads it?!
wookie77
08/10/2016
02:53
Pharmaceutical giant AstraZeneca (AZN) will divest its rights to market Rhinocort Aqua outside of the United States for $330 million (£265.1 million). The company said that the deal would let it focus its respiratory arm on Asthma and COPD treatments. The shares climbed 60p to 5,086p. http://www.biopharmadive.com/news/astrazeneca-conducts-fourth-sale-this-week/427858/
ohisay
06/10/2016
16:55
Yes / thanks a lot timbo.
ohisay
Chat Pages: 20  19  18  17  16  15  14  13  12  11  10  9  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:30 V: D:20161208 00:13:40